LEP and breast carcinoma: Similar results were observed following treatment with fatostatin (Fig. 5G), a pharmacological inhibitor of SREBPs, suggesting that SREBP‐1 critically contributes to induction of fatty acid synthesis under leptin stimulation in breast cancer cells.